Global Long-acting Anti-HIV Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Long-acting Anti-HIV Drug market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Long-acting anti-HIV drugs provide effective treatment options for HIV-infected people and have been widely recognized by the market. With the continuous deepening of research and development and the growth of market demand, long-acting anti-HIV drugs are expected to play a greater role in the future.
The Global Info Research report includes an overview of the development of the Long-acting Anti-HIV Drug industry chain, the market status of Hospital (CAB Long-acting Injection, RPV Long-acting Injection), Clinic (CAB Long-acting Injection, RPV Long-acting Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Long-acting Anti-HIV Drug.
Regionally, the report analyzes the Long-acting Anti-HIV Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Long-acting Anti-HIV Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Long-acting Anti-HIV Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Long-acting Anti-HIV Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., CAB Long-acting Injection, RPV Long-acting Injection).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Long-acting Anti-HIV Drug market.
Regional Analysis: The report involves examining the Long-acting Anti-HIV Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Long-acting Anti-HIV Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Long-acting Anti-HIV Drug:
Company Analysis: Report covers individual Long-acting Anti-HIV Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Long-acting Anti-HIV Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Long-acting Anti-HIV Drug. It assesses the current state, advancements, and potential future developments in Long-acting Anti-HIV Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Long-acting Anti-HIV Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Long-acting Anti-HIV Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Long-acting Anti-HIV Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Anti-HIV Drug, with price, sales, revenue and global market share of Long-acting Anti-HIV Drug from 2019 to 2024.
Chapter 3, the Long-acting Anti-HIV Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Anti-HIV Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Long-acting Anti-HIV Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Anti-HIV Drug.
Chapter 14 and 15, to describe Long-acting Anti-HIV Drug sales channel, distributors, customers, research findings and conclusion.
Long-acting anti-HIV drugs provide effective treatment options for HIV-infected people and have been widely recognized by the market. With the continuous deepening of research and development and the growth of market demand, long-acting anti-HIV drugs are expected to play a greater role in the future.
The Global Info Research report includes an overview of the development of the Long-acting Anti-HIV Drug industry chain, the market status of Hospital (CAB Long-acting Injection, RPV Long-acting Injection), Clinic (CAB Long-acting Injection, RPV Long-acting Injection), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Long-acting Anti-HIV Drug.
Regionally, the report analyzes the Long-acting Anti-HIV Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Long-acting Anti-HIV Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Long-acting Anti-HIV Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Long-acting Anti-HIV Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., CAB Long-acting Injection, RPV Long-acting Injection).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Long-acting Anti-HIV Drug market.
Regional Analysis: The report involves examining the Long-acting Anti-HIV Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Long-acting Anti-HIV Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Long-acting Anti-HIV Drug:
Company Analysis: Report covers individual Long-acting Anti-HIV Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Long-acting Anti-HIV Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Long-acting Anti-HIV Drug. It assesses the current state, advancements, and potential future developments in Long-acting Anti-HIV Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Long-acting Anti-HIV Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Long-acting Anti-HIV Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- CAB Long-acting Injection
- RPV Long-acting Injection
- Hospital
- Clinic
- Others
- Gilead
- ViiV Healthcare
- Janssen
- Tibotec
- Cipla
- Frontier Biopharmaceutical (Nanjing) Co., Ltd.
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Long-acting Anti-HIV Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Anti-HIV Drug, with price, sales, revenue and global market share of Long-acting Anti-HIV Drug from 2019 to 2024.
Chapter 3, the Long-acting Anti-HIV Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Anti-HIV Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Long-acting Anti-HIV Drug market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Anti-HIV Drug.
Chapter 14 and 15, to describe Long-acting Anti-HIV Drug sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Long-acting Anti-HIV Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Long-acting Anti-HIV Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 CAB Long-acting Injection
1.3.3 RPV Long-acting Injection
1.4 Market Analysis by Application
1.4.1 Overview: Global Long-acting Anti-HIV Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Long-acting Anti-HIV Drug Market Size & Forecast
1.5.1 Global Long-acting Anti-HIV Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Long-acting Anti-HIV Drug Sales Quantity (2019-2030)
1.5.3 Global Long-acting Anti-HIV Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Gilead
2.1.1 Gilead Details
2.1.2 Gilead Major Business
2.1.3 Gilead Long-acting Anti-HIV Drug Product and Services
2.1.4 Gilead Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Gilead Recent Developments/Updates
2.2 ViiV Healthcare
2.2.1 ViiV Healthcare Details
2.2.2 ViiV Healthcare Major Business
2.2.3 ViiV Healthcare Long-acting Anti-HIV Drug Product and Services
2.2.4 ViiV Healthcare Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 ViiV Healthcare Recent Developments/Updates
2.3 Janssen
2.3.1 Janssen Details
2.3.2 Janssen Major Business
2.3.3 Janssen Long-acting Anti-HIV Drug Product and Services
2.3.4 Janssen Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Janssen Recent Developments/Updates
2.4 Tibotec
2.4.1 Tibotec Details
2.4.2 Tibotec Major Business
2.4.3 Tibotec Long-acting Anti-HIV Drug Product and Services
2.4.4 Tibotec Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Tibotec Recent Developments/Updates
2.5 Cipla
2.5.1 Cipla Details
2.5.2 Cipla Major Business
2.5.3 Cipla Long-acting Anti-HIV Drug Product and Services
2.5.4 Cipla Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Cipla Recent Developments/Updates
2.6 Frontier Biopharmaceutical (Nanjing) Co., Ltd.
2.6.1 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Details
2.6.2 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Major Business
2.6.3 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product and Services
2.6.4 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: LONG-ACTING ANTI-HIV DRUG BY MANUFACTURER
3.1 Global Long-acting Anti-HIV Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Long-acting Anti-HIV Drug Revenue by Manufacturer (2019-2024)
3.3 Global Long-acting Anti-HIV Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Long-acting Anti-HIV Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Long-acting Anti-HIV Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Long-acting Anti-HIV Drug Manufacturer Market Share in 2023
3.5 Long-acting Anti-HIV Drug Market: Overall Company Footprint Analysis
3.5.1 Long-acting Anti-HIV Drug Market: Region Footprint
3.5.2 Long-acting Anti-HIV Drug Market: Company Product Type Footprint
3.5.3 Long-acting Anti-HIV Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Long-acting Anti-HIV Drug Market Size by Region
4.1.1 Global Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Long-acting Anti-HIV Drug Consumption Value by Region (2019-2030)
4.1.3 Global Long-acting Anti-HIV Drug Average Price by Region (2019-2030)
4.2 North America Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.3 Europe Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.5 South America Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Long-acting Anti-HIV Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
5.2 Global Long-acting Anti-HIV Drug Consumption Value by Type (2019-2030)
5.3 Global Long-acting Anti-HIV Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
6.2 Global Long-acting Anti-HIV Drug Consumption Value by Application (2019-2030)
6.3 Global Long-acting Anti-HIV Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
7.2 North America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
7.3 North America Long-acting Anti-HIV Drug Market Size by Country
7.3.1 North America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
8.2 Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
8.3 Europe Long-acting Anti-HIV Drug Market Size by Country
8.3.1 Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Long-acting Anti-HIV Drug Market Size by Region
9.3.1 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
10.2 South America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
10.3 South America Long-acting Anti-HIV Drug Market Size by Country
10.3.1 South America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Long-acting Anti-HIV Drug Market Size by Country
11.3.1 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Long-acting Anti-HIV Drug Market Drivers
12.2 Long-acting Anti-HIV Drug Market Restraints
12.3 Long-acting Anti-HIV Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Long-acting Anti-HIV Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Long-acting Anti-HIV Drug
13.3 Long-acting Anti-HIV Drug Production Process
13.4 Long-acting Anti-HIV Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Long-acting Anti-HIV Drug Typical Distributors
14.3 Long-acting Anti-HIV Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Long-acting Anti-HIV Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Long-acting Anti-HIV Drug Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 CAB Long-acting Injection
1.3.3 RPV Long-acting Injection
1.4 Market Analysis by Application
1.4.1 Overview: Global Long-acting Anti-HIV Drug Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Long-acting Anti-HIV Drug Market Size & Forecast
1.5.1 Global Long-acting Anti-HIV Drug Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Long-acting Anti-HIV Drug Sales Quantity (2019-2030)
1.5.3 Global Long-acting Anti-HIV Drug Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Gilead
2.1.1 Gilead Details
2.1.2 Gilead Major Business
2.1.3 Gilead Long-acting Anti-HIV Drug Product and Services
2.1.4 Gilead Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Gilead Recent Developments/Updates
2.2 ViiV Healthcare
2.2.1 ViiV Healthcare Details
2.2.2 ViiV Healthcare Major Business
2.2.3 ViiV Healthcare Long-acting Anti-HIV Drug Product and Services
2.2.4 ViiV Healthcare Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 ViiV Healthcare Recent Developments/Updates
2.3 Janssen
2.3.1 Janssen Details
2.3.2 Janssen Major Business
2.3.3 Janssen Long-acting Anti-HIV Drug Product and Services
2.3.4 Janssen Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Janssen Recent Developments/Updates
2.4 Tibotec
2.4.1 Tibotec Details
2.4.2 Tibotec Major Business
2.4.3 Tibotec Long-acting Anti-HIV Drug Product and Services
2.4.4 Tibotec Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Tibotec Recent Developments/Updates
2.5 Cipla
2.5.1 Cipla Details
2.5.2 Cipla Major Business
2.5.3 Cipla Long-acting Anti-HIV Drug Product and Services
2.5.4 Cipla Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Cipla Recent Developments/Updates
2.6 Frontier Biopharmaceutical (Nanjing) Co., Ltd.
2.6.1 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Details
2.6.2 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Major Business
2.6.3 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product and Services
2.6.4 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: LONG-ACTING ANTI-HIV DRUG BY MANUFACTURER
3.1 Global Long-acting Anti-HIV Drug Sales Quantity by Manufacturer (2019-2024)
3.2 Global Long-acting Anti-HIV Drug Revenue by Manufacturer (2019-2024)
3.3 Global Long-acting Anti-HIV Drug Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Long-acting Anti-HIV Drug by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Long-acting Anti-HIV Drug Manufacturer Market Share in 2023
3.4.2 Top 6 Long-acting Anti-HIV Drug Manufacturer Market Share in 2023
3.5 Long-acting Anti-HIV Drug Market: Overall Company Footprint Analysis
3.5.1 Long-acting Anti-HIV Drug Market: Region Footprint
3.5.2 Long-acting Anti-HIV Drug Market: Company Product Type Footprint
3.5.3 Long-acting Anti-HIV Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Long-acting Anti-HIV Drug Market Size by Region
4.1.1 Global Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2030)
4.1.2 Global Long-acting Anti-HIV Drug Consumption Value by Region (2019-2030)
4.1.3 Global Long-acting Anti-HIV Drug Average Price by Region (2019-2030)
4.2 North America Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.3 Europe Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.4 Asia-Pacific Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.5 South America Long-acting Anti-HIV Drug Consumption Value (2019-2030)
4.6 Middle East and Africa Long-acting Anti-HIV Drug Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
5.2 Global Long-acting Anti-HIV Drug Consumption Value by Type (2019-2030)
5.3 Global Long-acting Anti-HIV Drug Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
6.2 Global Long-acting Anti-HIV Drug Consumption Value by Application (2019-2030)
6.3 Global Long-acting Anti-HIV Drug Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
7.2 North America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
7.3 North America Long-acting Anti-HIV Drug Market Size by Country
7.3.1 North America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
7.3.2 North America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
8.2 Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
8.3 Europe Long-acting Anti-HIV Drug Market Size by Country
8.3.1 Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
8.3.2 Europe Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Long-acting Anti-HIV Drug Market Size by Region
9.3.1 Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
10.2 South America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
10.3 South America Long-acting Anti-HIV Drug Market Size by Country
10.3.1 South America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
10.3.2 South America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Long-acting Anti-HIV Drug Market Size by Country
11.3.1 Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Long-acting Anti-HIV Drug Market Drivers
12.2 Long-acting Anti-HIV Drug Market Restraints
12.3 Long-acting Anti-HIV Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Long-acting Anti-HIV Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Long-acting Anti-HIV Drug
13.3 Long-acting Anti-HIV Drug Production Process
13.4 Long-acting Anti-HIV Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Long-acting Anti-HIV Drug Typical Distributors
14.3 Long-acting Anti-HIV Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Long-acting Anti-HIV Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Long-acting Anti-HIV Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Gilead Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Major Business
Table 5. Gilead Long-acting Anti-HIV Drug Product and Services
Table 6. Gilead Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Gilead Recent Developments/Updates
Table 8. ViiV Healthcare Basic Information, Manufacturing Base and Competitors
Table 9. ViiV Healthcare Major Business
Table 10. ViiV Healthcare Long-acting Anti-HIV Drug Product and Services
Table 11. ViiV Healthcare Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. ViiV Healthcare Recent Developments/Updates
Table 13. Janssen Basic Information, Manufacturing Base and Competitors
Table 14. Janssen Major Business
Table 15. Janssen Long-acting Anti-HIV Drug Product and Services
Table 16. Janssen Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Janssen Recent Developments/Updates
Table 18. Tibotec Basic Information, Manufacturing Base and Competitors
Table 19. Tibotec Major Business
Table 20. Tibotec Long-acting Anti-HIV Drug Product and Services
Table 21. Tibotec Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Tibotec Recent Developments/Updates
Table 23. Cipla Basic Information, Manufacturing Base and Competitors
Table 24. Cipla Major Business
Table 25. Cipla Long-acting Anti-HIV Drug Product and Services
Table 26. Cipla Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Cipla Recent Developments/Updates
Table 28. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 29. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Major Business
Table 30. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product and Services
Table 31. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
Table 33. Global Long-acting Anti-HIV Drug Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 34. Global Long-acting Anti-HIV Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 35. Global Long-acting Anti-HIV Drug Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 36. Market Position of Manufacturers in Long-acting Anti-HIV Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 37. Head Office and Long-acting Anti-HIV Drug Production Site of Key Manufacturer
Table 38. Long-acting Anti-HIV Drug Market: Company Product Type Footprint
Table 39. Long-acting Anti-HIV Drug Market: Company Product Application Footprint
Table 40. Long-acting Anti-HIV Drug New Market Entrants and Barriers to Market Entry
Table 41. Long-acting Anti-HIV Drug Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 43. Global Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 44. Global Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 45. Global Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 46. Global Long-acting Anti-HIV Drug Average Price by Region (2019-2024) & (US$/Unit)
Table 47. Global Long-acting Anti-HIV Drug Average Price by Region (2025-2030) & (US$/Unit)
Table 48. Global Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 49. Global Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 50. Global Long-acting Anti-HIV Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 51. Global Long-acting Anti-HIV Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 52. Global Long-acting Anti-HIV Drug Average Price by Type (2019-2024) & (US$/Unit)
Table 53. Global Long-acting Anti-HIV Drug Average Price by Type (2025-2030) & (US$/Unit)
Table 54. Global Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 55. Global Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 56. Global Long-acting Anti-HIV Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 57. Global Long-acting Anti-HIV Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 58. Global Long-acting Anti-HIV Drug Average Price by Application (2019-2024) & (US$/Unit)
Table 59. Global Long-acting Anti-HIV Drug Average Price by Application (2025-2030) & (US$/Unit)
Table 60. North America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 61. North America Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 62. North America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 63. North America Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 64. North America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 65. North America Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 66. North America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 67. North America Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 68. Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 69. Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 70. Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 71. Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 72. Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 73. Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 74. Europe Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 75. Europe Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 76. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 77. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 78. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 79. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 80. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 81. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 82. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 83. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 84. South America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 85. South America Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 86. South America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 87. South America Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 88. South America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 89. South America Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 90. South America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 91. South America Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 92. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 93. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 94. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 95. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 96. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 97. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 98. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 99. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 100. Long-acting Anti-HIV Drug Raw Material
Table 101. Key Manufacturers of Long-acting Anti-HIV Drug Raw Materials
Table 102. Long-acting Anti-HIV Drug Typical Distributors
Table 103. Long-acting Anti-HIV Drug Typical Customers
LIST OF FIGURE
s
Figure 1. Long-acting Anti-HIV Drug Picture
Figure 2. Global Long-acting Anti-HIV Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Type in 2023
Figure 4. CAB Long-acting Injection Examples
Figure 5. RPV Long-acting Injection Examples
Figure 6. Global Long-acting Anti-HIV Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 7. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Application in 2023
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. Others Examples
Figure 11. Global Long-acting Anti-HIV Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Long-acting Anti-HIV Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Long-acting Anti-HIV Drug Sales Quantity (2019-2030) & (K Units)
Figure 14. Global Long-acting Anti-HIV Drug Average Price (2019-2030) & (US$/Unit)
Figure 15. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of Long-acting Anti-HIV Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 18. Top 3 Long-acting Anti-HIV Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Top 6 Long-acting Anti-HIV Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 22. North America Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. South America Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Type (2019-2030)
Figure 29. Global Long-acting Anti-HIV Drug Average Price by Type (2019-2030) & (US$/Unit)
Figure 30. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Application (2019-2030)
Figure 32. Global Long-acting Anti-HIV Drug Average Price by Application (2019-2030) & (US$/Unit)
Figure 33. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Canada Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Mexico Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. France Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. United Kingdom Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Russia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Italy Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 53. China Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Japan Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Korea Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. India Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Southeast Asia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Australia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Argentina Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 68. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 69. Turkey Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Egypt Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Saudi Arabia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. South Africa Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Long-acting Anti-HIV Drug Market Drivers
Figure 74. Long-acting Anti-HIV Drug Market Restraints
Figure 75. Long-acting Anti-HIV Drug Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drug in 2023
Figure 78. Manufacturing Process Analysis of Long-acting Anti-HIV Drug
Figure 79. Long-acting Anti-HIV Drug Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Table 1. Global Long-acting Anti-HIV Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Long-acting Anti-HIV Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Gilead Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Major Business
Table 5. Gilead Long-acting Anti-HIV Drug Product and Services
Table 6. Gilead Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Gilead Recent Developments/Updates
Table 8. ViiV Healthcare Basic Information, Manufacturing Base and Competitors
Table 9. ViiV Healthcare Major Business
Table 10. ViiV Healthcare Long-acting Anti-HIV Drug Product and Services
Table 11. ViiV Healthcare Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. ViiV Healthcare Recent Developments/Updates
Table 13. Janssen Basic Information, Manufacturing Base and Competitors
Table 14. Janssen Major Business
Table 15. Janssen Long-acting Anti-HIV Drug Product and Services
Table 16. Janssen Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Janssen Recent Developments/Updates
Table 18. Tibotec Basic Information, Manufacturing Base and Competitors
Table 19. Tibotec Major Business
Table 20. Tibotec Long-acting Anti-HIV Drug Product and Services
Table 21. Tibotec Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Tibotec Recent Developments/Updates
Table 23. Cipla Basic Information, Manufacturing Base and Competitors
Table 24. Cipla Major Business
Table 25. Cipla Long-acting Anti-HIV Drug Product and Services
Table 26. Cipla Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Cipla Recent Developments/Updates
Table 28. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 29. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Major Business
Table 30. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Product and Services
Table 31. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Long-acting Anti-HIV Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Frontier Biopharmaceutical (Nanjing) Co., Ltd. Recent Developments/Updates
Table 33. Global Long-acting Anti-HIV Drug Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 34. Global Long-acting Anti-HIV Drug Revenue by Manufacturer (2019-2024) & (USD Million)
Table 35. Global Long-acting Anti-HIV Drug Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 36. Market Position of Manufacturers in Long-acting Anti-HIV Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 37. Head Office and Long-acting Anti-HIV Drug Production Site of Key Manufacturer
Table 38. Long-acting Anti-HIV Drug Market: Company Product Type Footprint
Table 39. Long-acting Anti-HIV Drug Market: Company Product Application Footprint
Table 40. Long-acting Anti-HIV Drug New Market Entrants and Barriers to Market Entry
Table 41. Long-acting Anti-HIV Drug Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 43. Global Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 44. Global Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 45. Global Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 46. Global Long-acting Anti-HIV Drug Average Price by Region (2019-2024) & (US$/Unit)
Table 47. Global Long-acting Anti-HIV Drug Average Price by Region (2025-2030) & (US$/Unit)
Table 48. Global Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 49. Global Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 50. Global Long-acting Anti-HIV Drug Consumption Value by Type (2019-2024) & (USD Million)
Table 51. Global Long-acting Anti-HIV Drug Consumption Value by Type (2025-2030) & (USD Million)
Table 52. Global Long-acting Anti-HIV Drug Average Price by Type (2019-2024) & (US$/Unit)
Table 53. Global Long-acting Anti-HIV Drug Average Price by Type (2025-2030) & (US$/Unit)
Table 54. Global Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 55. Global Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 56. Global Long-acting Anti-HIV Drug Consumption Value by Application (2019-2024) & (USD Million)
Table 57. Global Long-acting Anti-HIV Drug Consumption Value by Application (2025-2030) & (USD Million)
Table 58. Global Long-acting Anti-HIV Drug Average Price by Application (2019-2024) & (US$/Unit)
Table 59. Global Long-acting Anti-HIV Drug Average Price by Application (2025-2030) & (US$/Unit)
Table 60. North America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 61. North America Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 62. North America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 63. North America Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 64. North America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 65. North America Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 66. North America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 67. North America Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 68. Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 69. Europe Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 70. Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 71. Europe Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 72. Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 73. Europe Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 74. Europe Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 75. Europe Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 76. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 77. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 78. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 79. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 80. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 81. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 82. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 83. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 84. South America Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 85. South America Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 86. South America Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 87. South America Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 88. South America Long-acting Anti-HIV Drug Sales Quantity by Country (2019-2024) & (K Units)
Table 89. South America Long-acting Anti-HIV Drug Sales Quantity by Country (2025-2030) & (K Units)
Table 90. South America Long-acting Anti-HIV Drug Consumption Value by Country (2019-2024) & (USD Million)
Table 91. South America Long-acting Anti-HIV Drug Consumption Value by Country (2025-2030) & (USD Million)
Table 92. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2019-2024) & (K Units)
Table 93. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Type (2025-2030) & (K Units)
Table 94. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2019-2024) & (K Units)
Table 95. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Application (2025-2030) & (K Units)
Table 96. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Region (2019-2024) & (K Units)
Table 97. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity by Region (2025-2030) & (K Units)
Table 98. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Region (2019-2024) & (USD Million)
Table 99. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value by Region (2025-2030) & (USD Million)
Table 100. Long-acting Anti-HIV Drug Raw Material
Table 101. Key Manufacturers of Long-acting Anti-HIV Drug Raw Materials
Table 102. Long-acting Anti-HIV Drug Typical Distributors
Table 103. Long-acting Anti-HIV Drug Typical Customers
LIST OF FIGURE
s
Figure 1. Long-acting Anti-HIV Drug Picture
Figure 2. Global Long-acting Anti-HIV Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Type in 2023
Figure 4. CAB Long-acting Injection Examples
Figure 5. RPV Long-acting Injection Examples
Figure 6. Global Long-acting Anti-HIV Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 7. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Application in 2023
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. Others Examples
Figure 11. Global Long-acting Anti-HIV Drug Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Long-acting Anti-HIV Drug Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Long-acting Anti-HIV Drug Sales Quantity (2019-2030) & (K Units)
Figure 14. Global Long-acting Anti-HIV Drug Average Price (2019-2030) & (US$/Unit)
Figure 15. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of Long-acting Anti-HIV Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 18. Top 3 Long-acting Anti-HIV Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 19. Top 6 Long-acting Anti-HIV Drug Manufacturer (Consumption Value) Market Share in 2023
Figure 20. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 22. North America Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 25. South America Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value (2019-2030) & (USD Million)
Figure 27. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Type (2019-2030)
Figure 29. Global Long-acting Anti-HIV Drug Average Price by Type (2019-2030) & (US$/Unit)
Figure 30. Global Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global Long-acting Anti-HIV Drug Consumption Value Market Share by Application (2019-2030)
Figure 32. Global Long-acting Anti-HIV Drug Average Price by Application (2019-2030) & (US$/Unit)
Figure 33. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 38. Canada Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 39. Mexico Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 45. France Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 46. United Kingdom Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. Russia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. Italy Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 53. China Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 54. Japan Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 55. Korea Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. India Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Southeast Asia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Australia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America Long-acting Anti-HIV Drug Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America Long-acting Anti-HIV Drug Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 64. Argentina Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 65. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa Long-acting Anti-HIV Drug Sales Quantity Market Share by Region (2019-2030)
Figure 68. Middle East & Africa Long-acting Anti-HIV Drug Consumption Value Market Share by Region (2019-2030)
Figure 69. Turkey Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 70. Egypt Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 71. Saudi Arabia Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. South Africa Long-acting Anti-HIV Drug Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Long-acting Anti-HIV Drug Market Drivers
Figure 74. Long-acting Anti-HIV Drug Market Restraints
Figure 75. Long-acting Anti-HIV Drug Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Long-acting Anti-HIV Drug in 2023
Figure 78. Manufacturing Process Analysis of Long-acting Anti-HIV Drug
Figure 79. Long-acting Anti-HIV Drug Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
